The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more effective than anastrozole alone in patients with hormone-receptor (HR)?positive metastatic breast cancer.
Postmenopausal women with previously untreated metastatic disease were randomly assigned, in a 1:1 ratio, to receive either 1 mg of anastrozole orally every day (group 1), with crossover to fulvestrant alone strongly encouraged if the disease progressed, or anastrozole and fulvestrant in combination (group 2). Patients were stratified according to prior or no prior receipt of adjuvant tamoxifen therapy.
The median progression-free survival was 13.5 months in group 1 and 15.0 months in group 2.
The combination therapy was generally more effective than anastrozole alone in all subgroups, with no significant interactions?more
Source: http://eurohealth.ie/2012/08/21/anastrozole-and-fulvestrant-in-metastatic-breast-cancer/
tracy morgan ground hogs day 2012 goundhog day punxsutawney facebook ipo facebook ipo egypt soccer riot
No comments:
Post a Comment